1-5 of 5
Tomasz Sacha, MDPhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Multicenter Prospective Study on Efficacy and Safety of Ponatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Previous Therapy: A 3-Year Report

Tomasz Sacha, MDPhD, Elzbieta Szczepanek, Paulina Dumnicka, PhD, Joanna Gora-Tybor, MD PhD, Joanna Niesiobedzka-Krezel, MDPhD, Witold Prejzner, MD PhD, Ewa Wasilewska, MDPhD, Janusz Kloczko, MDPhD, Hanna Ciepluch, MD, Wioletta Makowska, MD, Elzbieta Patkowska, MD, Joanna Wasilewska, MD, Grazyna Bober, MD, Malgorzata Kopera, MDPhD, Ryszard Wichary, MD, Renata Kroll-Balcerzak, MDPhD, Tomasz Gromek, MDPhD, Malgorzata Wach, MDPhD, Anna Rudkowska-Kazanowska, MD, Magdalena Swiniarska, MD, Edyta Paczkowska, MDPhD, Ewa Medras, MD, Monika Joks, MD, Marta Oller, MD, Renata Kasza, MD, Aleksandra Kostyra, MD, Justyna Gil, MD, Olga Grzybowska-Izydorczyk, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-141523
Published: 2020
Journal Articles

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Jorge E. Cortes, MD, Jane Apperley, FRCP, FRCPath, MB, Andreas Hochhaus, MD, Michael J. Mauro, MD, Philippe Rousselot, MDPhD, Tomasz Sacha, MDPhD, Moshe Talpaz, MD, Charles Chuah, MD, Jeffrey H. Lipton, MD PhD, Michael W. Deininger, MD PhD, Charles A. Schiffer, MD, Lori J. Maness, MD, James K. McCloskey, MD, Valentín García Gutiérrez, MD PhD, Hugues de Lavallade, MD PhD, Gabriel Etienne, MD PhD, Vickie Lu, PhD, Shouryadeep Srivastava, MBBS, PhD, Gianantonio Rosti, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-135883
Published: 2020
Journal Articles

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Srdan Verstovsek, MD PhD, Miklos Egyed, MD PhD, Ewa Lech-Marańda, MD PhD, Tomasz Sacha, MDPhD, Viviane Dubruille, MD, Stephen T. Oh, MD, Doroteya Todorieva-Todorova, MD, Francesco Passamonti, MD, Blanca Xicoy, MD, Björn Andréasson, MD PhD, Daniel El Fassi, MD, Claire Harrison, DM, FRCP, FRCPath, Donal P. McLornan, MRCP, PhD FRCPath, Mary Frances Frances McMullin, MDFRCPath,FRCP, Christof Scheid, MD, MArianne Tang Severinsen, MD PhD, Mark M Kowalski, MD PhD, Gregg Smith, PhD, Ruben Mesa, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 51–52.
https://doi.org/10.1182/blood-2020-135872
Published: 2020
Journal Articles

Long-Term Outcomes of Imatinib Real-Life Treatment for Chronic Myeloid Leukemia- a 20-Year Review

Elzbieta Szczepanek, MD, Ositadima Chukwu, Magdalena Kaminska, Hubert Wysoglad, Agnieszka Cenda, Joanna Waclaw, MD, Magdalena Zawada, MDPhD, Magdalena Jakobczyk, Tomasz Sacha, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 52–53.
https://doi.org/10.1182/blood-2020-140835
Published: 2020
Journal Articles

ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia

Francois-Xavier Mahon, MD PhD, Nelma D Clementino, MD, Mikhail Fominykh, MD, Jeffrey H. Lipton, MD PhD, Anna G. Turkina, Prof., MD, Beatriz Moiraghi, MD, Franck E Nicolini, MDPhD, Naoto Takahashi, MD PhD, Tomasz Sacha, MDPhD, Dong-Wook Kim, MD, Rafik Fellague-Chebra, MD, Ranjan Tiwari, MSc, Catherine Bouard, Timothy P. Hughes, MDMBBS,FRACP,FRCPA
Journal: Blood
Blood (2020) 136 (Supplement 1): 29–30.
https://doi.org/10.1182/blood-2020-136250
Published: 2020